ADAPTIN BIO Trademark
ADAPTIN BIO is a USPTO trademark filed by Adaptin Bio, Inc.. Status: Pending.
Trademark Facts
| Mark | ADAPTIN BIO |
|---|---|
| Serial Number | 98746952 |
| Status | Pending |
| Filing Date | 2024-09-12 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 042 (Software & IT) |
| Owner | Adaptin Bio, Inc. |
| Attorney of Record | Devon E. White |
| Prosecution Events | 24 |
| Latest Event | ERTD on 2026-04-16 |
Goods & Services
Biological preparations for treatment of cancers, central nervous system diseases and autoimmune disorders; Medical preparations and pharmaceuticals for treatment of cancers, central nervous system diseases and autoimmune disorders; Drug delivery agents in the form of an injectable liquid suspension that facilitate delivery of pharmaceutical preparations; Drug delivery platform, namely, drug delivery agents in the nature of cellular products being an injectable liquid suspension that facilitates delivery of pharmaceuticals; Pharmaceutical preparations for the treatment of cancers, central nervous system diseases and autoimmune disorders using compounds comprising of manipulated immune cells; Biological preparations for use in the manufacture of pharmaceuticals; "BIO"; Research in the field of biotechnology and pharmaceutical development; Research and development of platform technologies for delivery of therapies; Research and development of platform technologies for delivery of antibody therapies, cell therapies and pharmaceuticals; Research and development regarding the use of immune system cells to discover, research and develop novel platform technologies for delivery of therapies and pharmaceuticals; Pharmaceutical research and development for the treatment of cancers, neurological diseases, and neurological disorders and autoimmune disorders; Scientific research in the field of drug delivery platforms, cell therapies and pharmaceuticals; Pharmaceutical research services; Research and development of pharmaceutical preparations for treatment of cancers, neurological diseases and disorders and autoimmune diseases; Research and development in the fields of pharmaceuticals and biotechnology; Research and development regarding the delivery of drug therapies across the blood-brain barrier and other physiological barriers; Research and development regarding the delivery of drug and cell therapies to targeted body tissue; Research and development regarding the identification and targeting of specific cells for drug therapies